Sugi Predict

Sugi Predict / Compounds / SCHEMBL1407014

SCHEMBL1407014

SCHEMBL1407014

CC(C)(C)[Si](C)(C)OC1CCCCC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MAOA P21397 6/20 0.35
▸ POLB P06746 3/20 0.35
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559895 1.00 CA1 (0.39) CA1CA2CA4KMT2AALDH1A1
SCHEMBL8578128 0.95 MAOA (0.34) CA1CA2CA4KMT2AALDH1A1
SCHEMBL30726654 0.87 STAT3 (0.32) —
SCHEMBL3438152 0.81 CA1 (0.45) CA1CA2CA4KMT2AALDH1A1
SCHEMBL9285252 0.79 STAT3 (0.31) —
SCHEMBL30459802 0.77 STAT3 (0.32) —
SCHEMBL15032471 0.76 PPM1D (0.30) —
SCHEMBL6396660 0.75 TRIM24 (0.36) CA1CA2CA4KMT2AALDH1A1
SCHEMBL15032472 0.75 TLR4 (0.36) —
SCHEMBL9621403 0.74 FKBP1A (0.32) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946138-A And ring nitrogen-containing compound, intermediate thereof, preparation method and application 杭州圣域生物医药科技有限公司 2024-04-30 — — CN disclosed
EP-3521289-B1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2021-11-04 — — US disclosed
EP-3521289-A1 MNK INHIBITORS AND METHODS RELATED THERETO Effector Therapeutics Inc. (US) 2019-08-07 — — EP disclosed
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2019-07-11 — — US disclosed
US-20180085368-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. (NL) 2018-03-29 — — US disclosed
US-9814718-B2 MNK inhibitors and methods related thereto EFFECTOR THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
US-9814718-B2 MNK inhibitors and methods related thereto EFFECTOR THERAPEUTICS, INC. (US) 2017-11-14 — — US disclosed
US-20170266185-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2017-09-21 — — US disclosed
US-20170266185-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2017-09-21 — — US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 — — EP disclosed
US-7728029-B2 Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-06-01 — — US disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 — — WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 — — US disclosed
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase ANDERSON KEVIN WILLIAM 2007-09-27 — — US disclosed
EP-1032384-A4 CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO INC (US) 2001-11-21 — — EP disclosed
US-6207823-B1 ANTIBIOTIC; ANTIBIOTIC RESISTANT INFECTIONS MERCK & CO., INC. 2001-03-27 — — US disclosed
EP-1032384-A1 CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT Merck & Co., Inc. (US) 2000-09-06 — — EP disclosed
WO-1999020270-A1 CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 1999-04-29 — — WO disclosed
US-5597932-A Intermediate for the preparation of 19-nor vitamin D compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1997-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase HSD3B2, HSD3B1, HSD17B2 CA1 1704/4885CA2 2305/4885CA4 2998/4885
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 CA1 2661/4885CA2 1104/4885CA4 2290/4885
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 CA1 3510/4885CA2 3929/4885CA4 4825/4885
US-20180085368-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 CA1 2661/4885CA2 1104/4885CA4 2290/4885
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 CA1 2661/4885CA2 1104/4885CA4 2290/4885
US-20170266185-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 CA1 2661/4885CA2 1104/4885CA4 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.